September 14, 2022: Not only is the Omicron variant of the coronavirus spreading faster and reducing vaccine capacity for us, but it’s also more likely to take common home tests, according to new research.
Researchers designed 3 immediate antigen tests for home use: Flowflex (Acon Laboratories); MPBio (Biomedical MP); and Clinitest (Siemens-Healthineers) after the appearance of Omicron.
They found that the ability of tests to correctly identify a positive pattern reduced the occurrence of Omicron, from 87% to 81% for Flowflex; 80% to 73% for MPBio; and 83% to 70% for Clinitest. However, the decrease was only considered statistically significant for Clinitest.
But throat samples taken with non-unusual nose samples increased the sensitivity of MPBio to 83% and Clinitest to 77%. The mixing was not done with Flowflex.
Only one complied with the WHO bar
But even with nose and throat patterns, a singles test, MPBio, met World Health Organization sensitivity criteria of at least 80 percent and the ability to identify a negative pattern at least 97 percent of the time in other people with symptoms.
The study, published in the journal The BMJ Suggests, included another 6,497 people with COVID-19 symptoms over the age of 16 who presented for review at three fitness service review sites in the Netherlands between Dec. 21 and Feb. 10.
Trained gave all tested participants a PCR test and then participants were asked to take an antigen test at home as soon as possible, within 3 hours of their scale at the test site. They then completed a questionnaire.
Nasal autosampling was only used at the start of Omicron and when Omicron accounted for more than 90% of infections (Phase 1 study). When Omicron accounted for 99% of infections, the test moved to Phase 2 and combined throat and nose sampling.
The authors state that their effects show that other people with symptoms can count on an immediate positive antigen test result, regardless of which variant they possess, “while other people with a negative result in the self-test adhere to general preventive measures because a false-negative result cannot be governed outside.
The authors write that check marks deserve to update their commands so that they come with throat and nose samples.
Other: Adding throat tests is the answer
However, Timothy Feeney, BMJ studies editor, and Charles Poole, Ph. D. and associate professor in the Department of Epidemiology at the University of North Carolina, Chapel Hill, writes in a similar editorial that the answer is to add throat swabs to nasal tests.
They point out that the sensitivity is only higher than 77. 3% and 83% when throat sampling is added.
They also note that the tests were inconsistent: MPBio had much greater sensitivity when the nose and throat were tested, while Clinitest’s improvement was less dramatic.
“However, no test has reached the point of functionality announced by manufacturers,” they write.
It’s also unclear, they say, how many at-home tests can be expanded to include nasal and throat swabs.
Feeney and Poole underscore the political implications.
In the UK and the US, they write, policies on verification to resume general activities are “conf, poorly explained and frequently replaced. “in many situations. In the UK, however, government rules recommend that a negative result “means it is most likely not contagious”.
Poole told the BMJ, “Given the less-than-ideal functionality of antigen verification, rule updates in the public and personal sectors take this into account when suggesting actions based on verification results,” according to a press release.
In addition, other people deserve their scenario in deciding what steps to take after verification results, editorialists say, adding whether they have COVID-like symptoms, have been exposed to an inflamed person, have been in a high-risk indoor environment, or have enough time. passed with exposure to build up a higher viral load.
© 2005 – 2022 WebMD LLC. All rights reserved.
WebMD provides medical advice, diagnosis or treatment.
See more information.